Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Amine Oxidase Inhibitors and Development of Neuroprotective Drugs

Author(s): Bernard N. Sowa, Kathryn G. Todd, A. M. I Tanay, Andrew Holt and Glen B. Baker

Volume 2 , Issue 2 , 2004

Page: [153 - 168] Pages: 16

DOI: 10.2174/1570159043476800

Price: $65

Abstract

Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.

Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine

Next »

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy